The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Bein, I'll keep saying it. Launch and Coris are fine. The existing business is losing the cash. That's based on my reading of them swallowing some integration costs and the costs of the deal. If it transpires they actually bring nothing then I'll admit my assumptions are wrong. At that point, there'd be a real challenge in offloading them. If as I think they'll bring in enough to show profitability, I still think they'll need to make the Dx division better fit for sale as no one will buy it without a decent return. (Unless HCI do us a favour and find another biotech to shove it on to!). The finances will be interesting.
That’s all the discussion was Thompi, before the shouty man had his latest fit. I’ve basically made three points, the strategy was fine (positive), the purchases are profitable (positive), the original Dx arm is a bag of cr.p (oh no, put me on a naughty agenda fuelled list or debate it). Incidentally, only one mention of WaffAl, we’ve heard nothing on expansion, hardly an incoherent rant as the incoherent ranty man suggested.
Also I said the same as you just have, we’ve been promised profitability and they need to get it in shape before flogging it. A discussion point (what? On this board?), at the point it’s profitable, why not keep it, certainly don’t sell it cheap. Why not bin the original part, stop pretending you’ll ever develop tests and stick with the acquisitions that are cash generating.
Apre, the post I made that triggered the weird shouty man was criticism of Dx. Have you anything to say on topic or are you only capable of writing posts like that. We've all seen them before. I'm not biting. Offer a view on the business for a change. Happy with the raise? Pleased with the strategy? Thoughts on Dx plans? Assume you're delighted with Tx data? Pleased with the leadership? I'm interested in discussing the company if that's ok.
Not interested Apre. I'll voice my opinion. If you don't like it bin it. Same goes for you... If you're not capable of understanding that not everything smells of roses, so be it. Keep the pom poms flying high. I've always been critical of Alan and I'll continue to be.
It’s shame thompi, you’d have thought they could have used the growing pains from the LFT saga and used that knowledge to make some progress. I’ll not be sad to see Dx go.
Boohoo NY, childish ranting bizarrely angry moron. You’re clearly incapable of reasoned debate and my days of bickering with brain dead idiots that add nothing are behind me, sorry. I note you had nothing at all to say on topic, surprise surprise. Off to the bin amongst such luminaries as slacker246 and jwbellamy, a proud day. Enjoy fluffing eggy et al xx
U ok hun? It was a discussion about Dx. It’s clearly a pile of cr.p, the businesses they’ve bought are the clear highlight. I’ve discussed a strategy for it, what have you contributed recently other than fluffing eggy? Have a closer look at your own ironically angry posting. Developing and commercialising what? Affimers? They’ve had them long enough and they’re planning on selling Dx. Tells you what they think of their chances of developing Dx products.
When there are discussions about Tx I sing their praises, incredible tech with huge potential. All the patience in the world for that, which is just as well given Alan’s ability to forecast. If you can’t handle a balanced poster then best wrap your squidgy head in cotton wool and get yourself in a padded room, wet wipe.
Why is abakta Dx loss making? Errr because it's never achieved anything since its inception and never will. Cool story about developing tests, what's it been up to the decade before? Nowt other than burning cash. There are aspects of this business that are not good, thankfully outweighed by Tx. Get your pom poms out for absolutely everything if you fancy.
IPad, they're still profitable. They're just now part of a loss making division. Launch... Profitable. Coris... Profitable. Steaming pile of abakta Dx turds... Loss making. Add them up and you lose money. The businesses they've bought should turn Dx positive this year.
Well, we’ve been told it’ll be profitable in H2. We’ll get an idea of trajectory in the results. They need to get a wriggle on if that’s the plan for funding AVA6k to approval. So…Expect a 20p raise.
I disagree. They bought profitable businesses.
They then walloped in the costs from the existing Dx operation and wiped them out. They can sell what they bought, but at what price. If it's a loss then it's inexcusable. They need to trim the fat, see through the promises of expansion in to Germany (another vague pile of waffAl not followed up on) and get the division in to a saleable state OR get it contributing cash and keep it. Not a half way house.
The Dx strategy was fine. If properly executed. If it generated enough cash to cover heights and add some cash in the pot brilliant, why wouldn’t you. The issue is that we’ve not seen those profits and as soon as we do, the for sale sign goes up. Two stupid wrong decisions don’t make a right as the net result is as simple as pouring cash away for absolutely no benefit.
That’s what happened the last time he chatted to Paul Hill Donkey and that’s why I think he needs to get out of the way. He should be all over the strategy, it should be nailed down rather than fumbling around to see where the can has landed for the next hoof. I thought it was the usual superlative display. As in a display of superlatives. Oooh I felt all warm and cosy until I looked at the share price.
Notrex, if you’ve spotted a change in tune it’ll be because the trading position will have changed. That’s what makes the sealion one of the vilest biggest pricks.
Thought it was excellent given pre treatment and the stage the patients were at. Dox is 65%, but it can only be given for so long. Ava6k ticks the boxes to become SoC. Even with the same efficacy the reduced side effects make the difference, with optimisation you can add the potential for better efficacy.